Phase 2b RCT | ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis.

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

Among patients with moderate-to-severe #ulcerativecolitis who had not responded or were intolerant to previous treatment, all three doses of obefazimod (ABX464) resulted in significantly greater reductions from baseline in modified Mayo score by week 8 vs placebo #gitwitter #IBD https://t.co/oDcQaEFVKp

— Rob Brierley (@Rob__Brierley) September 6, 2022